Oral contraceptive-associated hypertension as an under-recognized contributor to secondary and apparent resistant hypertension: agent-specific blood pressure liability, RAAS testing pitfalls, and practical assessment.

Oral contraceptive-associated hypertension is a long-recognized yet still under-recognized and potentially reversible contributor to elevated blood pressure in women, particularly adolescents and young adults. In Japan, prescribing of low-dose estrogen-progestin preparations has increased; however, available prescription data neither demonstrate an increase in oral contraceptive-associated hypertension nor establish a pill-specific rise in blood pressure among young women. Hormonal exposure may be overlooked because patients may not identify hormonal pills as blood pressure-relevant medicines and because contraceptive prescribing and hypertension assessment often occur in separate clinical settings. Oral contraceptive use may contribute to new-onset hypertension, worsening of established hypertension, apparent resistant hypertension, and misinterpretation of renin-angiotensin-aldosterone system testing. Blood pressure liability varies by formulation: ethinyl estradiol-containing combined hormonal contraceptives warrant the greatest concern, whereas drospirenone-containing or estradiol-based combined pills, progestin-only pills, and implants generally have lower or more neutral blood pressure signals. This review integrates targeted exposure recognition, formulation-specific assessment, home and ambulatory blood pressure monitoring, practical interpretation of a mildly elevated aldosterone-to-renin ratio, and coordinated management of women with new, worsening, or apparent resistant hypertension.